

1

2 **Supplemental Fig. S1.** Representative GUS staining of *pMYB89:GUS*
3 transgenic plants shows MYB89 expression in true leaves **(A)** and a root tip **(B)**
4 of a 15-day-old young seedling. Bar = 200 µm.

5

6

7

8

9

10

11

12

13

14

15

16

17


18

19

20

21

22



23

24 **Supplemental Fig. S2.** Comparison of the plant size between the wild-type
25 (Col-0) and *myb89-1* plants. The photographs were taken 23 days after sowing
26 under the same controlled conditions.

27

28

29

30

31


32

33

34

35

36



37

38 **Supplemental Fig. S3.** Comparison of the wild-type (Col-0) and *myb89-1*
39 young seedlings under stressed environments. The photographs were taken
40 20 days after sowing and show the situations on the control medium (without
41 stress, CK), MS agar medium containing 2.5% (w/v) Glucose (Glc), and MS
42 agar medium containing 75 mM NaCl.


43

44

45

46

47



48

49 **Supplemental Fig. S4.** Effect of *MYB89* knockdown in the wild-type (Col-0)
 50 background and *MYB89* overexpression in *myb89-1* mutant background on
 51 seed size and seed weight. For each construct (*35S:RNAi-MYB89* and
 52 *35S:MYB89-6HA*), four independent homozygous T3 transgenic lines with the
 53 strongest effect on *MYB89* expression were selected and analysed. Values are
 54 means \pm SD (n = 5), and each of the three assays for each biological replicate
 55 contains 200 seeds from 12 individual plants grown in different pots arranged
 56 randomly within one of the three blocks. Asterisks indicate significant
 57 differences in the seed total FA content compared to that in the wild-type
 58 (ANOVA, Tukey's test, $P \leq 0.05$).


59 **(A)** Quantitative comparison of seed size [length (Left column) and width
 60 (Right column)] between the wild-type (Col-0) and *35S:RNAi-MYB89*
 61 transgenic plants.

62 **(B)** Quantitative comparisons of seed dry weight between the wild-type (Col-0)
 63 and *35S:RNAi-MYB89* transgenic plants.

64 **(C)** Quantitative comparison of seed size [length (Left column) and width
 65 (Right column)] between the wild-type (Col-0) and *myb89-1 35S:MYB89-6HA*
 66 transgenic plants.


67 **(D)** Quantitative comparisons of seed dry weight between the wild-type (Col-0)
 68 and *myb89-1 35S:MYB89-6HA* transgenic plants.

69
 70



71

72 **Supplemental Fig. S5.** Effect of altering *MYB89* expression on seed number
 73 (A), seed yield (B), and oil yield (C). Values are means \pm SD of measurements
 74 on seeds from individual plants ($n = 12$) of each genotype grown under the
 75 same controlled conditions. Asterisks indicate significant differences compared
 76 to the wild-type (two-tailed paired Student's *t* test, $P \leq 0.05$).




77

78 **Supplemental Fig. S6.** qRT-PCR analysis of the expression of genes involved
 79 in FA biosynthesis and TAG deposition in developing seeds of the wild-type
 80 (Col-0) and *myb89-1* plants. Solid and dotted lines indicate the dynamic
 81 expression of genes in the wild-type and *myb89-1* plants, respectively. Results
 82 were normalised against the expression levels of *EF1aA4* as an internal
 83 control. Values are means \pm SD (n = 3). No significant differences in
 84 expression levels of these genes in *myb89-1* compared with those in the
 85 wild-type plants were observed (two-tailed paired Student's *t* test, $P \leq 0.05$).

86

87



88

89 **Supplemental Fig. S7.** Confirmation of the biologically active MYB89-GR
90 fusion. Seedlings of *myb89-1 35S:MYB89-GR* were mock-treated (Mock) or
91 treated with 10 µM dexamethasone (Dex) every alternate day after
92 germination. The seed FA content of mock-treated plants was similar to that of
93 *myb89-1* plants, whereas dexamethasone treatment rescues this phenotype to
94 the wild-type (Col-0) level. Values are means ± SD (n = 5).

95


96

97

98

99

100



101

102 **Supplemental Fig. S8.** The genes involved in glycolysis, FA biosynthesis and
 103 modification, and TAG deposition in developing seeds are not immediate
 104 targets of transcriptional regulation by MYB89 in developing seeds. The
 105 *myb89-1 35S:MYB89-GR* siliques at 12 DAP were mock-treated (Mock) or
 106 treated with 10 μ M dexamethasone (DEX), 10 μ M cycloheximide (CYC), or 10
 107 μ M CYC plus 10 μ M DEX (DEX + CYC), and siliques at 14 DAP were used for
 108 the transcriptional analysis of *FAD2*, *FAD3*, *FAE1*, and *ROD1*. The expression
 109 of these genes was examined after 4 h of treatment by qRT-PCR analyses.
 110 Results were normalised against the expression of *EF1aA4* as an internal
 111 control. Values are means \pm SD (n = 3). Asterisks indicate significant
 112 differences in gene expression in dexamethasone-treated samples compared
 113 with their respective controls (two-tailed paired Student's *t* test, $P \leq 0.05$).

114

115

116

117


118

119

120

121

122



123

124 **Supplemental Fig. S9.** qRT-PCR analysis of the expression of six *BPM* genes
 125 in developing seeds of the wild-type (*Col-0*) and *myb89-1* plants. Solid and
 126 dotted lines indicate the dynamic expression of genes in the wild-type and
 127 *myb89-1* plants, respectively. Results were normalised against the expression
 128 levels of *EF1aA4* as an internal control. Values are means \pm SD ($n = 3$). No
 129 significant differences in expression levels of these genes in *myb89-1*
 130 compared with those in the wild-type plants were observed (two-tailed paired
 131 Student's *t* test, $P \leq 0.05$).

132